Illumina Q2 2025 slides: revenue declines 3% while margins expand, SomaLogic acquisition announced

Illumina Inc. (ILMN) reported mixed Q2 2025 results, with revenue declining 3% year-over-year to $1.06 billion, though profitability improved as non-GAAP operating margin expanded to 23.8% and EPS rose 9% to $1.19. The genomic sequencing leader also announced the strategic acquisition of SomaLogic for up to $425 million to bolster its multiomics capabilities. Despite these strategic moves and margin expansion, the stock declined, reflecting investor concerns over persistent revenue headwinds, which led to a revised full-year 2025 revenue guidance projecting a continued decline of 0.5% to 2.5%.

Analysis

Illumina Inc. presented a mixed Q2 2025 financial report, demonstrating resilient profitability in the face of persistent revenue headwinds. The company reported a 3% year-over-year revenue decline to $1.06 billion, driven by an 18% drop in sequencing instruments revenue and a significant 14% constant currency contraction in Greater China. This top-line weakness prompted a downward revision of full-year 2025 revenue guidance to a decline of between 0.5% and 2.5%. Despite these challenges, management executed effectively on cost controls, expanding the non-GAAP operating margin by 160 basis points to 23.8% and boosting non-GAAP EPS by 9% to $1.19. Strategically, Illumina is positioning for future growth through the $350 million acquisition of proteomics firm SomaLogic to accelerate its multiomics strategy and by driving the transition to its NovaSeq X platform, which saw over 50 new instrument placements and double-digit quarter-over-quarter growth in consumables revenue. The company's financial position remains solid, evidenced by $204 million in free cash flow and a $380 million share repurchase during the quarter, though the negative stock reaction underscores investor concern that operational efficiency may not be enough to offset the near-term revenue pressures.

Key Decisions for Investors

• Investors should weigh Illumina's proven ability to expand margins and generate strong cash flow against its persistent revenue declines and lowered full-year guidance, which signal continued near-term market challenges.
• Closely monitor the adoption rate and consumables revenue growth from the NovaSeq X platform, as the success of this transition is critical to offsetting instrument sale weakness and securing long-term market leadership.
• Factor in the strategic potential of the SomaLogic acquisition to create a key player in the multiomics space, while remaining cognizant of integration risks and the use of capital for M&A during a period of organic revenue contraction.
• Evaluate the significant and ongoing risk in the Greater China region, which saw a 14% revenue drop and has a weak Q3 forecast, and consider its impact on the company's ability to meet its overall financial targets.
• Note that the aggressive share buyback program provides a degree of valuation support, but also represents a significant capital allocation choice amidst ongoing investments in R&D and strategic acquisitions.